1. Catalog
  2. Nonalcoholic Fatty Liver Disease: An Emerging Epid ...
Image For Activity Cover
Nonalcoholic Fatty Liver Disease: An Emerging Epidemic?
Course Description
 
Accreditation and Designation Statements
 
Learning Objectives
 
Target Audience
 
Disclosures and Conflicts of Interest
 
Commercial Support
 
List of Faculty
 
Disclaimer
 
Number of Faculty Members
 
Number of Lectures
 
Engaged Member Price
 
Informed Member Price
 
Non-Member Price
 
Purchase URL
https://my.aace.com/manage-subscriptions
Faculty
Scott D. Isaacs, MD, FACP, FACE 
Adjunct Assistant Professor of Medicine
Emory University School of Medicine

Scott Isaacs, MD, FACP, FACE is the co-chair of AACE Fatty Liver Clinical Practice Guidelines, a member of the AACE executive committee and board of directors. He is Adjunct Assistant Professor of Medicine at Emory University School of Medicine. Dr. Isaacs attended Emory College and Emory University School of Medicine, continuing for his residency in Internal Medicine and Fellowship in Endocrinology. Dr. Isaacs is a Fellow of the American College of Physicians and the American College of Endocrinology and is a Diplomate of the American Board of Obesity Medicine. He is a two-time past president of Georgia AACE, past president of the Atlanta Chapter of the Atlanta Diabetes Association.
Accreditation Information

Accreditation and Designation Statements:

The American College of Endocrinology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Learning Objectives

Through this education, learners will improve their abilities to:

    • Describe the epidemiology, pathophysiology and natural history of NAFLD as the hepatic manifestation of the metabolic syndrome.
    • Compare non-invasive testing modalities to detect patients at risk for clinically significant liver fibrosis.
    • Summarize the latest management recommendations from the AACE NAFLD Clinical Practice Guidelines.

Target Audience

This educational initiative is intended for all members of the endocrine care team.

Disclosure and Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE)requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Faculty​

  • Scott D. Isaacs, MD, FACP, FACE
    Nothing to disclose

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Summary
Availability: Retired
Cost: FREE
Credit Offered:
No Credit Offered
Powered By